Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture

A clinical trial involving 29 adult B-ALL patients used equal proportions of CD4+ and CD8+ T cells to manufacture anti-CD19 CAR-T cells, which yielded remarkable effects even though these subsets were manufactured separately (NCT01865617).7 Nevertheless, these studies highlight the importance of mai...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2024-03, Vol.12 (3), p.e008723
Main Authors: Melenhorst, J Joseph, Oliveira, Beatriz C
Format: Article
Language:English
Subjects:
Antigens
Biomarker
Cancer
Cells
Chimeric antigen receptor - CAR
Clinical trials
Commentary
Cytokines
Genotype & phenotype
Hematology
Immunotherapy
Leukemia
Lymphocytes
Patients
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A clinical trial involving 29 adult B-ALL patients used equal proportions of CD4+ and CD8+ T cells to manufacture anti-CD19 CAR-T cells, which yielded remarkable effects even though these subsets were manufactured separately (NCT01865617).7 Nevertheless, these studies highlight the importance of maintaining CAR-T cells in a less differentiated state and having both subsets present within the product to more likely achieve long-term functionality and avoid T cell dysfunction. Conclusion Identifying the ideal composition of CAR-T-cells requires careful evaluation in preclinical models and mechanistic studies, as they provide important information about the biological and molecular components of the various subtypes of T cells and tumor cells, which must be taken into account when designing new or improved products. Despite the fact that there was no significant gap to be filled regarding the role of CD4+ T cells in helping CD8+ T cells in preserving their function and proliferation during CAR-T manufacture, this study confirmed previous observations on in vitro and in vivo contexts.
ISSN:2051-1426
2051-1426
DOI:10.1136/jitc-2023-008723